DUBLIN, January 21, 2022--(BUSINESS WIRE)--The "Cancer Cachexia - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Global Cancer Cachexia Market to Reach US$2.8 Billion by the Year 2026
Global market for Cancer Cachexia estimated at US$2.1 Billion in the year 2020, is projected to reach a revised size of US$2.8 Billion by 2026, growing at a CAGR of 4.6% over the analysis period.
Progestogens, one of the segments analyzed in the report, is projected to grow at a 4.7% CAGR to reach US$1.1 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Corticosteroids segment is readjusted to a revised 4.1% CAGR for the next 7-year period.
This segment currently accounts for a 24.7% share of the global Cancer Cachexia market. Progestogens represent the largest segment, due to the low cost, safety and effectiveness. Progestogens improve appetite and aid in weight gain. Corticosteroids are generally used by medical professionals for stimulating appetite. Researchers have investigated oral dexamethasone in randomized trials involving cancer patients. These trials indicated the potential of the drug to improve appetite and non-fluid weight gain.
Growth in the global market is set to be driven by rising incidence of cancer globally, and increasing R&D funding to develop novel and sophisticated treatment options with certain mode of action. The market growth is favored by increasing attention on palliative cancer care along with rising incidence of cancer.
Treatment modalities for cancer cachexia include appetite stimulants and drugs. There are several pipeline drugs in the late stages of clinical trials, for cancer cachexia treatment, which are anticipated to be commercialized over the coming two to three years. This is also expected to drive market growth.
Combination Therapies Segment to Reach $639.7 Million by 2026
Recent therapy developments in the treatment of cancer cachexia have been combination therapies, supplemented with exercise routines and modification in diets. Pharmaceutical agents like medroxyprogesterone and megestrol among others are being used along with exercise and diet for improving survival rates and quality for life.
In the global Combination Therapies segment, USA, Canada, Japan, China and Europe will drive the 5.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$396.7 Million in the year 2020 will reach a projected size of US$576.6 Million by the close of the analysis period.
China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$48.4 Million by the year 2026.
The U.S. Market is Estimated at $879.7 Million in 2021, While China is Forecast to Reach $232.6 Million by 2026
The Cancer Cachexia market in the U.S. is estimated at US$879.7 Million in the year 2021. The country currently accounts for a 40.07% share in the global market. China, the world's second largest economy, is forecast to reach an estimated market size of US$232.6 Million in the year 2026 trailing a CAGR of 6.5% through the analysis period.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR while Rest of European market (as defined in the study) will reach US$250.2 Million by the end of the analysis period.
Presence of several major drug manufacturers in the region coupled with the factor of increasing number of cancer patients and need for care for the patients promotes dominance of North America region. Market growth in Asia-Pacific region is due to growing geriatric population and increasing awareness about supportive care for cancer patients both among healthcare professionals and patients.
Key Topics Covered:
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Cancer - An Insight
A Prelude to Cancer Cachexia
Pharmacologic Approaches for Clinical Management of Cancer Cachexia
Cytokines & Neuro-Hormones
Impact of COVID-19 on Cancer Cachexia Market
Global Market Prospects and Outlook
Global Cancer Cachexia Market Set for a Rapid Growth
Progestogens Account for a Major Share, Combination Therapies to Drive Growth
North America and Europe Constitute Major Regions, Asia-Pacific Exhibits the Fastest Growth
Based on Mechanism of Action
Recent Market Activity
2. FOCUS ON SELECT PLAYERS (Total 29 Featured)
AVEO Pharmaceuticals, Inc.
Boehringer Ingelheim International GmbH.
Eli Lilly and Company
Helsinn Healthcare SA
Marsala Biotech Inc.
MetaFines Co., Ltd.
3. MARKET TRENDS & DRIVERS
Rise in Cancer Cases, and High Prevalence of Cancer Cachexia to Drive Market Growth
Numerous Efforts Underway to Improve Therapy for Cancer Presents Lucrative Opportunities
Promising Treatment Options Drive Market Gains
IL-1a, IL-6 & TNFa Inhibitors
Appetite & Metabolism Modulators
New Potential Therapeutic Options
Ageing Demographics to Drive Market Demand
Uptrend in Healthcare Spending Drives Market Demand
Cancer Research Spending Continues to Witness Growth
Macimorelin from AEterna Zentaris
PF- 06946860 from Pfizer
TCMCB07 from Endevica Bio
Select Unimodal Treatment Agents for Cancer Cachexia Currently Under Clinical Trial
Combination of Medical Therapeutics and Nutritional Interventions to Provide Better Outcome
Select Key Developments
Helsinn Launches Adlumiz for Cancer Cachexia Patients in Japan
Researchers Secure Program Project Grant to Uncover Biology behind Cancer Cachexia
Researchers Develop New Drug with Potential to Improve & Treat Cancer Cachexia
Actimed Therapeutics Plans to Advance Lead Compound for Cancer Cachexia
ESMO Publishes New Guidelines on Cachexia Management in Adult Cancer Patients
4. GLOBAL MARKET PERSPECTIVE
III. REGIONAL MARKET ANALYSIS
For more information about this report visit https://www.researchandmarkets.com/r/uakijq
View source version on businesswire.com: https://www.businesswire.com/news/home/20220121005302/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900